This post was contributed by Miranda Weston-Smith, who on 10 March was a guest speaker at an event hosted by the Transforming Institutions by Gendering contents and Gaining Equality in Research (TRIGGER) team – a research project in Birkbeck’s Department of Management.

At a joint Birkbeck School of Science and TRIGGER event, Miranda Weston-Smith discussed her experiences in founding BioBeat together with opportunities for scientists and business graduates in bio-sciences. Miranda helps early stage biomedical businesses attract investment and develop their business strategies.

Miranda has worked with many entrepreneurs and is experienced in fundraising, business planning and technology transfer. She is a long standing Mentor for Cambridge Judge Business School’s Entrepreneurship Centre, contributes to the University of Cambridge Masters in Bioscience Enterprise course and is a member of the St John’s Innovation Centre Training Team.

Miranda studied Natural Sciences at the University of Cambridge and has a Diploma from the Chartered Institute of Management Accountants.

 

She brings experience as a Technology Manager at Cambridge Enterprise, where she assessed and marketed life science technologies, negotiated licences and spun-out companies. She was responsible for technology transfer at the University of Cambridge for the Cambridge-MIT Institute. In her five years at the seed capital firm, Cambridge Research and Innovation, she invested in early stage technologies. Miranda co-founded Cambridge Network with Hermann Hauser.

 

As a result of working with researchers, Miranda founded and runs BioBeat, a programme to inspire the next wave of bio-entrepreneurs and business leaders. It is a way to engage with successful women entrepreneurs and she explained that in her experience women adopt different strategies to issues such as working in teams, risks, and raising finance. Doctor Helen Lee, Director of Research, Department of Haematology, University of Cambridge and Founder, Diagnostics for the Real World, and Dr Jane Osbourn, Vice President Research and Development, MedImmune and Head of Site MedImmune Cambridge were hugely important catalysts for BioBeat getting underway and for the first Bio Beat conference in 2013, with an all-female panel.

Introducing the Cambridge bio cluster

Miranda introduced the Cambridge bio cluster that involved a range of organisations involved in medicines, R&D Support, clinical diagnostics and consumer health. Many of the companies involved in these areas have connections with Cambridge University. Those involved in medicines may have direct intellectual property (IP) relationships with University. For others, the relationships may be more indirect through networking between individuals and groups.

Miranda discussed the differences between the Cambridge biocluster of 2010 and of 2015. Lines are much tighter and investment has significantly increased through a range of funders. For example, Axol Bioscience after setting out to obtain £600,000 through a crowdfunding campaign, managed to bring in £1 million.

On advice for entrepreneurs, Miranda stressed that it is Important to find out where strengths of a company lie. The company needs to find where it sits in the market – where its customers are – and then funding can speed-up. For example, one company set out to exploit exhalation technology through non-invasive equipment that was developed as a veterinary product for horses and other animals. However, having discovered that managing severe breathing attacks such as asthma costs the NHS over £1 billion per year, the company is now developing the technology for human patients. The approval procedure, finances and returns are completely different in these two sectors.

Another aspect stressed by Miranda is linking-up the product and the market with the financial details. Investors are really interested in the two aspects of market and finance as well as the product, so providing projections of three-year cash-flows can be very important. Investors will be seeking creativity in potential problem-solving from an early stage.

Q&A

Miranda then took questions in a lively session during which most delegates to the seminar participated by asking specific questions or joining in the discussion that ensued.

The first question related to the institutional anchors that underpin the bio-science cluster. Miranda said that Cambridge University provided local industry links and was there as a strong, constant presence. The corporates that are present are a mainstay that can provide sponsorship as well as international connections and perspectives. BioBeat is also a way of opening up fresh energies and a way of encouraging people to do more.

In answer to later questions about the university’s role, Miranda confirmed that the institution does not usually seek absolute control of enterprises, but tries to support incubate, and accelerate ideas. Cambridge University’s IP policy is that of retention of the first right to file patent applications; but copyright rests with the researchers. This means that there are many ways to exploit the ideas and not just go through the University. In addition, Cambridge Enterprises puts in seed money, but this is generally done in a low key way. Generally the University sees itself as an enabler and incubator.

A series of questions and some discussion followed about how to get involved in networking from a student business perspective, rather than as a scientific researcher. Miranda suggested that the first thing to do is to just try it after scoping-out what events are going on. Miranda candidly admitted that when she first started, she didn’t really understand what networking was all about and that you have to learn on the job. Porosity and being interested in what others are doing are important. Also, if you go out with one or two colleagues, it is important not just to stand together; just go up to people and start talking to them.

In the discussion it was mentioned that potential entrepreneurs could attend interesting networking events. Such events are regularly attended by service providers, head-hunters, institutions and sometimes investors. In London, One Nucleus holds regular events. Miranda confirmed the value of attending them.

Asked about how the Cambridge bio-cluster compared with others in Europe, Miranda suggested that one of ways is to look at companies that are moving into the area, such as   Ilumina. Microsoft has its European R&D office in Cambridge. Astra Zeneca (AZ) already has various laboratories around Cambridge, but eventually some 1600 – 2000 people will move in to their new building. The impact on the cluster will be for example, there will be opportunities for sub-contracting work and for early stage collaborative projects.

Finally, on the subject of how Miranda saw the cluster evolving, she said she expected Cambridge University to continue to spin-out biotech companies, and with spin-outs from other companies, the cluster will grow further. Spin-outs will also come from Barbaham Institute and Addenbrookes Hospital and from companies such Illumina.

Find out more

• TRIGGER (Twitter: @TRIGGERbbk)
• School of Science
• Department of Management
• MWS Consulting (Twitter: @BioBeatUK)